The care ofobesity with RNA it is closer, in the Turin laboratories. Resalis Therapeutics, in fact, closed a round up with a massive investment on the part of SanofiFrench pharmaceutical giant. Still Top Secret the amount, but it must certainly be sufficient for the decisive impulse for research.
Alessandro Toniolo, CEO of scale up based in Turin, in via De Sonnaz, declared: “We are preparing to start the clinical study of Phase 1 per RES-010. This investment not only validates i solid data that we have generated so far, but allows us to quickly advance through the studies of Phase 2bringing us closer to offering a potentially transformative treatment for patients suffering from obesity”.
The Resalis Therapeutics specializes in research on therapies based on RNA for the treatment of metabolic dysfunctions. Among these is obesity which is the main target of short-term scale up research. In recent times, the Turin company had received financing for 10 million euros from the Investors Club, with the business angels, which followed the six million euro one from the Claris Venturesa biotech investment firm that recently signed a partnership with Exor by John Elkann. And, last February, Claris Ventures also participated in a 10 million euro round up led by Sunstone Life Science Ventures.
As for Sanofi, the Parisian group is the result of a series of mergers that start from the ancient Rhone in the medical and pharmaceutical sector and has a turnover of around 38 million euros. And, as Toniolo underlines, he has shown that he believes in the potential of RES-010RES-010 which is described as a drug which has the potential to go beyond the conventional treatments of obesity, which often focus exclusively on reducing appetite, as with therapy of RNA actually “redesigns” metabolic dysfunctions.
